Last updated: July 22, 2026
Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc., No. 3:18-cv-04273, is a Hatch-Waxman patent infringement case filed in the District of New Jersey. The case is tied to Teva’s FDA ANDA activity for a Gilead product and includes the standard Orange Book-driven infringement allegations for at least one listed patent, with likely Paragraph IV content tied to Teva’s proposed generic launch. A full, litigation-ready summary requires the operative complaint, asserted patent list, and the procedural docket events; these are not present in the available input.
What happened in Gilead v. Teva 3:18-cv-04273? (case timeline and procedural posture)
The case caption and docket number indicate a Hatch-Waxman dispute between Gilead (patent owner) and Teva (ANDA filer). Without the docket’s event history and order text, a complete timeline (complaint filing date, service, answer, claim construction, summary judgment, trial, or settlement) cannot be accurately reconstructed.
What procedural events typically define 3:18-cv-04273 cases?
For Hatch-Waxman matters in federal district court, key milestones usually include:
- Complaint filing and asserted-patent identification
- Answer and any counterclaims
- Claim construction (Markman) schedule
- Dispositive motions (Daubert, summary judgment on noninfringement/invalidity, unenforceability, or claim construction)
- Consent/settlement orders (common in Paragraph IV disputes)
- Judgment entry and case disposition
No docket entries or court orders are provided here, so no specific dates or rulings can be stated.
Which patents did Gilead assert against Teva in 3:18-cv-04273?
The decisive element for infringement analysis is the Orange Book patent list and the specific patents asserted in the complaint (including any method-of-use, formulation, or formulation-permitted claims tied to the drug product). The asserted patent numbers, expiration dates, and claim categories are not included in the available input.
How the asserted patent set shapes infringement outcomes
In Hatch-Waxman litigation, the outcome and bargaining value typically depend on whether the asserted patents are:
- Composition or formulation patents (harder design-around, but invalidity often argued via obviousness or lack of enablement)
- Method-of-use patents (often easier to steer around through label changes or noninfringing use design)
- Manufacturing process patents (manufacturing and process discovery become central)
- Combination product claims (scope tied to drug regimen labeling)
Without the patent list, no claim-strength or design-around analysis can be done for this case.
What is the Orange Book status tied to the Teva ANDA behind this case?
Hatch-Waxman cases hinge on the FDA Orange Book listing at the time of ANDA submission. The product name, NDA/ANDA numbers, and the listed patents that drove the Paragraph IV notice are not provided.
What you normally extract for Orange Book-driven litigation analysis
A litigation-ready Orange Book section typically includes:
- Listed drug (RLD) and dosage form (tablet, capsule, film-coated, etc.)
- Patents by number, type (drug substance, drug product, use), and expiration
- Exclusivity periods (5-year/3-year, pediatric, patent term extension if applicable)
- Whether Teva filed a Paragraph IV or other certification
No Orange Book data is present in the input, so the Orange Book status cannot be stated.
Did Teva file a Paragraph IV certification in 3:18-cv-04273?
Paragraph IV certification is generally required to trigger the statutory 30-month stay and the parallel infringement litigation structure. The input does not identify the certification type (Paragraph I, II, III, or IV) and does not list the specific patent(s) to which Teva certified.
Why Paragraph IV certification changes the litigation posture
- Paragraph IV filing drives immediate infringement allegations tied to the listed patent(s).
- If settlement occurs, it usually locks in entry dates and/or licensing terms based on the statutory framework.
- The 30-month stay timing depends on the timing of the notice and the court process.
No certification facts are provided.
What were Gilead’s infringement theories and claim constructions?
Claim construction determines infringement scope and validity defenses. The operative infringement contentions, claim charts, and any Markman rulings are not included.
What infringement themes are common in Gilead patent estates
Gilead disputes often involve:
- Compound and composition claims (scope tied to structural/formula elements)
- Pharmaceutical formulation claims (excipients, polymorphs, or process parameters)
- Method-of-use claims (drug regimen and therapeutic indication constraints)
Without asserted claim language or rulings, no credible mapping can be made.
What invalidity and unenforceability arguments did Teva raise?
Invalidity arguments in this category often include:
- Obviousness over prior art combinations
- Anticipation by earlier disclosures
- Lack of written description or enablement
- Inequitable conduct and patent prosecution-based defenses
The input provides no motion papers, no court rulings, and no asserted prior art.
Was the case dismissed, settled, or decided on the merits?
Disposition is typically determined by:
- Settlement and consent judgment
- Voluntary dismissal
- Summary judgment resolving infringement/invalidity
- Trial verdict and final judgment
- Appellate outcomes
No case disposition text, judgment docket number, or settlement record is included.
What settlement terms or licenses affected Teva’s launch timing?
In many Hatch-Waxman disputes, settlement agreements drive:
- Noninfringement or covenant-not-to-sue periods
- Royalty structures or paid-up licenses
- Agreed design-arounds and label restrictions
- Entry dates that align with patent or exclusivity expiration
The input includes no settlement agreement or entry-date language.
How does this litigation compare with other Gilead v. generic cases?
A comparative analysis requires identifying:
- Same product and patent family across multiple defendants
- Similar claim categories (drug product vs. method)
- Common invalidity theories and outcomes across cases
No product/patent identifiers are present, so no cross-case patterning can be done.
What is the commercial and regulatory impact of 3:18-cv-04273 for Teva and Gilead?
Commercial impact depends on:
- Which Gilead product the ANDA targets
- Expected market size and launch sequencing
- Whether the outcome blocks, delays, or permits generic entry
No drug identity, ANDA status, or outcome is available in the input.
Key Takeaways
- The case number (3:18-cv-04273) confirms a Hatch-Waxman-style patent dispute between Gilead and Teva, but the provided input does not include the operative complaint, asserted patent list, docket events, or disposition.
- Without asserted patents, Orange Book linkage, and court orders, no definitive infringement/invalidity analysis, no exclusivity or launch-date impact, and no settlement or decision summary can be stated accurately.
FAQs
- What patents are listed in the Orange Book for the Gilead RLD tied to 3:18-cv-04273?
- What ANDA product and ANDA number did Teva pursue that triggered Gilead’s infringement suit?
- What court orders or claim construction rulings were issued in 3:18-cv-04273?
- Did Gilead obtain an injunction, consent judgment, or summary judgment in this matter?
- What entry date or launch restrictions resulted from any settlement in 3:18-cv-04273?
References
- Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc., No. 3:18-cv-04273 (D.N.J.).
